Briacell Therapeutics 's Cash & cash equivalent grew by 27.64 % in the Q3 2026 sequentially, while Current Liabilities decreased, this led to improvement in Briacell Therapeutics 's Quick Ratio to 6.35, Quick Ratio remained below Briacell Therapeutics Corp average.

Within Major Pharmaceutical Preparations industry 162 other companies have achieved higher Quick Ratio than Briacell Therapeutics in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 367 to 538.

Explain Quick Ratio?
How much Cash & cash equivalents BCTX�s has?
What are BCTX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

BCTX Quick Ratio	(Apr 30 2026) Q3	(Jan 31 2026) Q2	(Oct 31 2025) Q1	(Jul 31 2025) Q4	(Apr 30 2025) Q3
Y / Y Current Liabilities Change	-17.09 %	-46.68 %	-33.49 %	-46.68 %	-35.92 %
Y / Y Cash & cash equivalent Change	83.02 %	1972.44 %	75.68 %	1972.44 %	1231.66 %
Quick Ratio MRQ	6.35	4.49	3.07	4.49	2.88
BCTX's Total Ranking	# 538	# 367	# 770	# 552	# 938
Seq. Current Liabilities Change	-9.74 %	19.9 %	-16.6 %	-8.14 %	-41.96 %
Seq. Cash & cash equivalent Change	27.64 %	75.57 %	-43.04 %	43.39 %	1345.36 %

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 163
Healthcare Sector	# 250
Overall Market	# 538

Quick Ratio Statistics
High	Average	Low
202.9	31.3	0.12
(Jul 31 2021)		(Jul 31 2024)

Financial Statements
Briacell Therapeutics 's Current Liabilities	$ 4 Millions	Visit BCTX's Balance sheet
Briacell Therapeutics 's Cash & cash equivalent	$ 23 Millions	Visit BCTX's Balance sheet
Source of BCTX's Sales		Visit BCTX's Sales by Geography

Cumulative Briacell Therapeutics 's Quick Ratio

BCTX's Quick Ratio for the trailling 12 Months

BCTX Quick Ratio	(Apr 30 2026) 12 Months	(Jan 31 2026) 12 Months	(Oct 31 2025) 12 Months	(Jul 31 2025) 12 Months	(Apr 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-38.68 %	-41.49 %	-11.9 %	17.12 %	90.54 %
Y / Y Cash & cash equivalent TTM Growth	243.97 %	590.58 %	43.42 %	0.78 %	-65 %
Quick Ratio TTM	4.62	3.74	2.17	1.78	0.82
Total Ranking TTM	# 2889	# 2366	# 3022	# 3107	# 3526
Seq. Current Liabilities TTM Growth	-4.74 %	-18.25 %	-8.05 %	-14.37 %	-9.1 %
Seq. Cash & cash equivalent TTM Growth	17.72 %	41.11 %	11.85 %	85.12 %	136.35 %

Quick ratio ranking by company, industry and sector >> Back to BCTX Financial Strength Comparisons >> Go to Compare BCTX Quick Ratio to its Competitors

News about Briacell Therapeutics Corp Quick Ratio

BriaCells Bria-OTS Pioneering a Personalized Approach in Metastatic Breast Cancer Treatment,

Revolutionary Steps in Metastatic Breast Cancer Treatment: BriaCell s Innovative Bria-OTS Study Begins In a significant breakthrough for metastatic breast cancer treatment, BriaCell Therapeutics Corp. a dynamic force in the biotech industry, has announced the dosing of the first patient in its groundbreaking Phase 1/2 study. This milestone marks the debut of Bria-OTS, BriaCell s latest personalized next-generation immunotherapy that promises a new horizon in the battle against cancer.The study, registered under ClinicalTrials.gov identifier NCT06471673, undertakes a rigorous evaluation of the safety and efficacy of Bria-OTS. This cutting-edge therapeutic approach is designed to tailor treatment uniquely to each patient s cancer profile, potentially transforming how metastatic breast cancer is managed. The study also explores the potential of using Bria-OTS in combination with the immune checkpoint inhibitor tislelizumab, in collaboration with BeiGene, Ltd.

On the trailing twelve months basis BCTX Cash & cash equivalent soared by 83.02 % in Q3 2026 year on year, while Current Liabilities decreased to $4 millions, this led to increase in in Briacell Therapeutics 's Quick Ratio to 4.62, Quick Ratio remained below BCTX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 396 other companies have achieved higher Quick Ratio than Briacell Therapeutics . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2025 from 2366 to 2889.

Explain Quick Ratio?
How much Cash & cash equivalents BCTX�s has?
What are BCTX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 397
Healthcare Sector	# 802
Within the Market	# 2889

trailing twelve months Quick Ratio Statistics
High	Average	Low
35.32	8.49	0.52
(Apr 30 2023)		(Jan 31 2025)

Companies with similar Quick Ratio in the quarter ending Apr 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Apr 30 2026 MRQ Cash & cash equivalent	Apr 30 2026 MRQ Current Liabilities
Minerva Neurosciences Inc	17.42	$ 78.065 Millions	$ 4.482 Millions
Lexicon Pharmaceuticals Inc	17.24	$ 170.658 Millions	$ 9.898 Millions
Sellas Life Sciences Group Inc	16.60	$ 107.197 Millions	$ 6.456 Millions
Pliant Therapeutics Inc	16.50	$ 170.892 Millions	$ 10.359 Millions
Innoviva Inc	16.50	$ 603.085 Millions	$ 36.558 Millions
Dianthus Therapeutics Inc	16.29	$ 617.109 Millions	$ 37.884 Millions
Janux Therapeutics Inc	16.23	$ 956.386 Millions	$ 58.915 Millions
Praxis Precision Medicines Inc	16.12	$ 786.865 Millions	$ 48.806 Millions
Nuvalent Inc	15.88	$ 1,287.476 Millions	$ 81.051 Millions
Oric Pharmaceuticals Inc	15.86	$ 281.932 Millions	$ 17.771 Millions
Adc Therapeutics Sa	15.86	$ 231.008 Millions	$ 14.567 Millions
Protagonist Therapeutics inc	15.86	$ 547.786 Millions	$ 34.549 Millions
Aprea Therapeutics Inc	15.80	$ 46.466 Millions	$ 2.941 Millions
Emmis Acquisition Corp	15.64	$ 0.782 Millions	$ 0.050 Millions
Rezolute Inc	15.61	$ 120.268 Millions	$ 7.704 Millions
Bioage Labs Inc	15.38	$ 243.457 Millions	$ 15.827 Millions
An2 Therapeutics Inc	15.33	$ 85.288 Millions	$ 5.562 Millions
Roivant Sciences Ltd	15.26	$ 4,291.833 Millions	$ 281.244 Millions
Gri Bio Inc	15.01	$ 11.048 Millions	$ 0.736 Millions
Ocular Therapeutix Inc	14.98	$ 666.699 Millions	$ 44.513 Millions
Cogent Biosciences Inc	14.94	$ 866.378 Millions	$ 57.981 Millions
Pepgen Inc	14.76	$ 132.303 Millions	$ 8.964 Millions
Spruce Biosciences Inc	14.68	$ 54.080 Millions	$ 3.683 Millions
Coya Therapeutics Inc	14.30	$ 50.725 Millions	$ 3.547 Millions
Sensei Biotherapeutics Inc	14.29	$ 202.793 Millions	$ 14.190 Millions
Vtv Therapeutics Inc	14.25	$ 98.086 Millions	$ 6.881 Millions
Jade Biosciences Inc	13.96	$ 311.295 Millions	$ 22.292 Millions
Bicara Therapeutics Inc	13.72	$ 539.753 Millions	$ 39.340 Millions
Onkure Therapeutics Inc	13.41	$ 192.106 Millions	$ 14.329 Millions
Crescent Biopharma Inc	13.33	$ 189.163 Millions	$ 14.193 Millions

Date modified: 2026-09-17T09:32:25+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.